What is MOTS-c?

By ClearCost Wellness, a Dataweave Inc publication · Published 24 October 2026 · Updated 24 October 2026

In short: MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, sold in 10 mg vials for research use only. Studied in cell and animal models of metabolism; human evidence for administering it is largely preclinical. It is not FDA-approved. It was considered for the 503A compounding bulks list at the FDA advisory committee's July 2026 meeting; committee recommendations are non-binding advice to the FDA.

MOTS-c is a small peptide encoded not in the cell nucleus but in mitochondrial DNA - which is why it sits at the center of the "mitochondrial" longevity-research narrative. It is one of the fastest-rising compounds in the research-peptide market, and one of the most misrepresented.

The basics

• Type: a 16-amino-acid mitochondrial-derived peptide (MDP), encoded in the 12S rRNA region of mitochondrial DNA; first characterized in 2015.
• Research focus: laboratory studies examine MOTS-c in relation to metabolic regulation pathways (including AMPK signaling) and exercise-response biology in cell and animal models.
• Formats sold: lyophilized (freeze-dried) vials, most commonly 10 mg, with larger 40 mg vials also listed.
• Market stage: early and price-disordered - tracked prices for the same 10 mg item span a wide range across 252 tracked vendors (see below), which usually signals an immature market with room for both markups and mistakes.

What the evidence actually shows

Honestly stated: the human evidence for injected MOTS-c is largely preclinical. Most published human work measures endogenous MOTS-c levels and how they relate to exercise and metabolism - it does not establish that administering MOTS-c produces any particular effect in people. The mechanistic findings that generate the headlines come from cell cultures and animal models.

That gap - real scientific interest, unproven human effect - is exactly why this compound attracts exaggerated marketing. If a seller describes MOTS-c outcomes as established, that is a claim the current literature does not support.

Regulatory status (October 2026)

On 23-24 July 2026, the FDA's Pharmacy Compounding Advisory Committee considered MOTS-c for inclusion on the 503A Bulks List, the list of substances licensed pharmacies may use in compounding. Two things are equally true:

• Committee recommendations are non-binding advice to the FDA; inclusion on the list would require FDA rulemaking.
• The meeting was a nomination review, not a drug-approval process; MOTS-c is not FDA-approved.

MOTS-c is sold today in the research-chemical channel under "research use only" labeling. What that label does and does not mean is covered in our FAQ.

What MOTS-c costs

Price tracking by PeptidePrices (checked 24 October 2026) shows the lowest 10 mg listing at $15.31 across 252 tracked vendors. Tracked listings are not like-for-like: testing, documentation and coupon discounts differ between vendors, so the lowest listing is not proof of equivalent product. Trade-level prices sit far below retail, which is typical of this market and is the main reason comparison shopping matters.

See the full table, with vendor counts and check dates, on the price-comparison page.

What to check before buying any research peptide

• Batch-specific COA: a certificate of analysis tied to the lot in the vial, from third-party testing - not a generic PDF reused across products.
• Purity method: identity and purity should be verified by HPLC and mass spectrometry; the COA should say so.
• Price sanity: compare against the tracked market range above. Far-below-median pricing in this market correlates with the quality problems regulators keep finding.

Related reading

• What is Epithalon? - the other longevity-narrative compound in the July 2026 vote, with the weakest human evidence of the group.
• Research peptide price comparison - tracked prices for all four hero compounds plus market context.
• FAQ: the July 2026 FDA votes, "research use only," and COAs explained